Codexis Inc (CDXS) 2.30 $CDXS
Codexis' (CDXS) CEO John Nicols on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:50PM CST
CDXS: 2.30 (-0.10)
Codexis misses by $0.06, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:09PM CST
CDXS: 2.30 (-0.10)
Codexis Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014
GlobeNewswire - Tue Nov 04, 3:03PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced financial results for the third quarter and nine months ended September 30, 2014.
CDXS: 2.30 (-0.10)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.88 (-0.05), ITRI: 40.92 (-0.72), AWAY: 30.97 (+0.17), OKE: 55.65 (-0.81), HR: 25.84 (+0.10), NYMT: 8.11 (-0.01), OCLR: 1.68 (+0.03), ENPH: 10.64 (+0.01), ADEP: 8.66 (-0.28), CBSO: 31.08 (+0.27), NSTG: 12.19 (+0.03), MITT: 19.03 (-0.15), CRTO: 38.20 (+0.92), FOXA: 34.99 (+0.35), OKS: 47.88 (-0.10), JMBA: 12.70 (-0.02), IVR: 16.26 (+0.04), CSU: 23.42 (+0.42), MYGN: 33.35 (+0.36), JIVE: 6.93 (+0.26), GAS: 51.65 (-0.47), COUP: 16.00 (-0.01), NRP: 12.58 (-0.25), MOSY: 1.79 (+0.12), COHR: 58.14 (-0.74), DOX: 47.58 (-0.12), CKEC: 28.48 (+0.08), OAS: 25.72 (-0.65), PAYC: 22.60 (+0.25), PCYC: 137.80 (+0.43), AXLL: 42.99 (-0.24), NP: 57.67 (-0.27), BIRT: 3.69 (-0.11), ATVI: 20.33 (-0.08), EXAM: 37.73 (+0.04), P: 18.45 (-0.34), JAZZ: 172.98 (-0.55), PBPB: 13.61 (-0.09), EXEL: 1.76 (-0.05), CERS: 4.42 (+0.23), DVN: 63.28 (-0.79), FEYE: 33.34 (+0.19), CHUY: 22.25 (-0.24), FRGI: 56.43 (-0.24), GHDX: 32.77 (-0.22), PACD: 6.69 (-0.18), BIO: 111.54 (-0.39), BIOL: 2.34 (-0.03), JKHY: 60.50 (-0.33), KAR: 33.74 (+0.09), CDXS: 2.30 (-0.10), MPO: 2.94 (-0.25), FANG: 64.76 (-0.05), CORT: 3.05 (-0.01), CALD: 15.63 (-0.01)
Codexis Appoints Pam P. Cheng, Merck Global Executive, to Board of Directors
GlobeNewswire - Mon Nov 03, 3:01PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Pam Cheng to its board of directors. Ms. Cheng is a 17-year veteran of Merck & Co. and is currently serving as President of MSD China, where she has direct responsibility for $1.3 billion in sales and approximately 4,000 employees, covering a wide functional scope which includes commercial, R&D, manufacturing and various business support organizations.
MRK: 59.54 (+0.23), CDXS: 2.30 (-0.10)
Industrial Enzymes: Carbohydrases, Proteases, Lipases & Others - 2014 Global Strategic Business Report
M2 - Wed Oct 29, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrwq4b/industrial) has announced the addition of the "Industrial Enzymes - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Industrial Enzymes in US$ Thousands by the following Product Segments: - Carbohydrases - Proteases - Lipases - Others The report also analyzes the following End-Use Segments: - Food & Beverage - Detergents & Other Cleaning Products - Textiles - Animal Feed - Ethanol Production - Others The report profiles 52 companies including many key and niche players such as: - AB Enzymes GmbH - Advanced Enzyme Technologies Ltd. - Amano Enzyme Inc. - Asahi Kasei Pharma Corporation - BASF SE - BioResource International, Inc. - Chr. Hansen A/S - Codexis, Inc. - DuPont Nutrition and Health - Direvo Biotech AG - Enzymatic Deinking Technologies LLC - Hayashibara Company - Novozymes A/S - Royal DSM Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competition 3. Market Trends, Issues And Drivers 4. Product Overview 5. Product Introductions/Innovations 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. The Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 52 (including Divisions/Subsidiaries - 60) - The United States (18) - Canada (1) - Japan (3) - Europe (29) - - France (7) - - Germany (7) - - The United Kingdom (2) - - Spain (1) - - Rest of Europe (12) - Asia-Pacific (Excluding Japan) (
- Latin America (1) For more information visit http://www.researchandmarkets.com/research/hrwq4b/industrial
CDXS: 2.30 (-0.10)
Codexis reports November 4
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 7:39AM CDT
CDXS: 2.30 (-0.10)
Codexis to Report Third Quarter 2014 Financial Results on November 4
GlobeNewswire - Tue Oct 21, 7:11AM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will report third quarter financial results after the close of market on November 4, followed at 4:30 p.m. Eastern Time by a conference call and audio webcast at www.codexis.com.
CDXS: 2.30 (-0.10)
Market Maker Surveillance Report. AHPI, APT, LAKE, IBIO, CDXS, MPO, Losing Stocks With Lowest Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:11AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Allied Healthcare Products Inc (NASDAQ:AHPI), Alpha Pro Tech Ltd (NYSE:APT), Lakeland Industries Inc (NASDAQ:LAKE), Ibio Inc (NYSE:IBIO), Codexis Inc (NASDAQ:CDXS), Midstates Petroleum Company Inc (NYSE:MPO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
APT: 2.87 (-0.13), AHPI: 1.58 (-0.14), MPO: 2.94 (-0.25), CDXS: 2.30 (-0.10), IBIO: 1.08 (-0.03), LAKE: 11.39 (-0.85)
Codexis Appoints Biotechnology Industry Veteran, Kathleen Glaub, to Board of Directors
GlobeNewswire - Mon Sep 22, 7:07AM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Kathleen Sereda Glaub to its board of directors. Ms. Glaub's 30-year career in leadership positions with drug development and technology companies will bring strong company-building and business strategy experience to the Codexis board.
CDXS: 2.30 (-0.10)
Analyzing the Market for Cellulosic Ethanol - 2014
M2 - Wed Sep 17, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/38rww8/analyzing_the) has announced the addition of the "Analyzing the Market for Cellulosic Ethanol - 2014" report to their offering. This report is a complete handbook on this dynamic fuel source and its position in the global energy scenario. The report builds on the global energy industry and the consumption patterns which are fed by the traditional sources like Oil, Coal, Natural Gas, Nuclear Energy and Hydroelectricity. The report also presents a track on the global energy consumption patterns along with the resources being used for them. Taking into consideration the revenue cycles in the global energy markets, the report explains the revenue derived from these demand patterns from traditional sources as well as hydroelectric and wind energy. The report further also details each source individually. Taking a contrasting view point the report presents an in depth analysis of the global energy crisis and the growing recognition of unconventional energy sources for arresting this crisis. Key Topics Covered: A. Executive Summary B. Analyzing the Global Energy Industry C. Revenue Returns on Global Energy Markets D. Global Energy Demand & Supply Dynamics E. Looking at the Global Energy Crisis F. Emergence of Ethanol as an Energy Source G. Introduction to Cellulosic Ethanol H. Analyzing the Major Conversion Technologies: Producing Ethanol from Cellulosic Feedstocks I. Analyzing Ethanol Production from Different Feedstocks J. Analyzing the Utility of Ethanol in Transportation K. Commercializing Cellulosic Ethanol L. Factors Impact Growth of the Industry M. Challenges & Issues Facing the Industry N. Technological Patterns Prominent in the Industry O. Role of Industrial Biotechnology in the Development of Cellulosic Ethanol P. Production Patterns Q. Influence of Cellulosic Ethanol on the Farm Economy R. Ethanol Production and Use - Impact on the Economy S. Analyzing the Economics of Ethanol Production T. Analyzing the Regulatory Framework U. Government Incentives & Support Mechanisms V. Leading Industry Players - Abengoa Bioenergy Corporation - Archer Daniels Midland Co. - Aventine Renewable Energy Holdings - Cargill - Codexis, Inc - Dyadic International, Inc - Genencor International - Green Plains Renewable Energy. - Iogen Corporation - Lignol - Mascoma Corporation - NatureWorks, LLC - Novozymes - Pacific Ethanol, Inc. - Renova Energy (Wyoming Ethanol) - SunOpta - Tate & Lyle - The Andersons Inc. - U.S. BioEnergy Corporation - VeraSun Energy Corporation - Verenium - Xethanol BioFuels, LLC For more information visit http://www.researchandmarkets.com/research/38...lyzing_the
ADM: 50.81 (+0.10), GPRE: 33.01 (-0.60), CDXS: 2.30 (-0.10)
Global Synthetic Biology Market Forecasts and Opportunities, 2020
M2 - Tue Sep 02, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnnz65/global_synthetic) has announced the addition of the "Global Synthetic Biology Market (Products, Technologies, Applications and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. Global synthetic biology market was valued at $3.0 billion in 2013 and it is estimated to reach $38.7 billion by 2020, growing at a CAGR of 44.2% during the forecast period. Synthetic biology is a novel field that finds its origin at the intersection of biology and engineering. It involves designing and construction of biological systems or devices that can be applied in varied domains to get specified results. It's a multidisciplinary effort made by scientists to understand the functioning of biological organisms, cells & genes and implementation of artificial genetic processes to give specific characteristics to an organism. It can even be used to develop a completely new biological system. Assistance from government and private organizations, rising number of entities conducting research and declining cost of DNA sequencing and synthesizing are key driving factors of the market. Governments are providing funds to research organizations, assisting them to find novel applications of synthetic biology. Bio-safety & bio-security issues, ethical issues and regulations are key retraining factors of the market. The fact that synthetic biology can be misused has raised concerns all around the world. Further, there are possibilities of accidental release of pathogens or genetically modified organisms into free atmosphere. Report Scope Key Deliverables Market by Products - Enabling Products - DNA Synthesis - Oligonucleotide Synthesis - Enabled Products - Pharmaceuticals - Chemicals - Biofuels - Agriculture - Core Products - Synthetic DNA - Synthetic Genes - Synthetic Cells - XNA - Chassis Organisms Market by Technology - Enabling Technology - Genome Engineering - Microfluidics technologies - DNA synthesis & sequencing technologies - Bioinformatics technologies - Biological components and integrated systems technologies - Enabled Technology - Pathway engineering - Synthetic microbial consortia - Biofuels technologies Market by Application Research & Development - Chemicals - Agriculture - Pharmaceuticals & Diagnostics - Biofuels - Others (Environment, Biotechnology & Biomaterials, etc.) Companies Mentioned - Algenol Biofuels - BASF - BioAmber - BioSearch Technologies - Butamax Advanced Biofuels - Codexis Inc. - Dupont - GEN9 Inc. - Gensript Corporation - Origene Technologies - Synthetic Genomics For more information visit http://www.researchandmarkets.com/research/jn..._synthetic
CDXS: 2.30 (-0.10)
Codexis Reports Financial Results for the Second Quarter of 2014
GlobeNewswire - Wed Aug 06, 3:02PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced its financial results for the second quarter ended June 30, 2014.
CDXS: 2.30 (-0.10)
5 Stocks Ready for Breakouts
at The Street - Mon Aug 04, 9:14AM CDT
These stocks are within range of triggering breakout trades.
BLUE: 41.23 (+0.21), TSLA: 251.70 (+2.60), ZPIN: 15.02 (-0.98), OVTI: 26.62 (-0.38), CDXS: 2.30 (-0.10), ATRO: 50.88 (-0.80)
Codexis to Announce Second Quarter 2014 Financial Results on August 6, 2014
GlobeNewswire - Thu Jul 31, 3:43PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will host a live conference call and audio webcast on Wednesday, August 6, 2014 at 4:30 p.m. Eastern Time to discuss its second quarter 2014 financial results. The call and webcast will follow the release of second quarter financial results after market close. A recorded version of the call will be available approximately one hour after the call on the Investors section of the company's website, www.codexis.com, and will be archived for up to 30 days.
CDXS: 2.30 (-0.10)
Gordon Sangster to Join Codexis as Senior Vice President & Chief Financial Officer
GlobeNewswire - Mon Jul 28, 3:01PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that Gordon Sangster has agreed to join Codexis as Senior Vice President & Chief Financial Officer. Gordon, who will start on August 18, 2014, will manage all aspects of Codexis' financial and accounting functions and will report to John Nicols, President & Chief Executive Officer.
CDXS: 2.30 (-0.10)
Biotechnology Sector Trends Higher with Breakthrough Clinical Trials, Collaborations & License Agreements
PR Newswire - Wed Jul 16, 7:15AM CDT
Biotechnology Companies strive to improve cancer treatment and develop innovative therapies as biotech sector sees growth as well as registered success: GenSpera, Inc. (OTC: GNSZ), Codexis, Inc. (NASDAQ: CDXS), Eli Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Seattle Genetics (NASDAQ: SGEN).
JNJ: 109.07 (+0.32), SGEN: 36.89 (-0.91), PFE: 30.42 (unch), CDXS: 2.30 (-0.10), LLY: 67.68 (+0.28)
Why Codexis (CDXS) Stock Hit a One-Year High Today
at The Street - Tue Jul 15, 1:11PM CDT
Codexis (CDXS) soared to a 52-week high of $2.65 on Tuesday after the biocatalyst developer announced a technology licensing agreement with GlaxoSmithKline (GSK).
CDXS: 2.30 (-0.10)
Codexis licenses its protein engineering platform technology to GlaxoSmithKline
M2 - Tue Jul 15, 8:24AM CDT
Biocatalysts company Codexis (NasdaqGS:CDXS) disclosed on Monday the execution of a platform technology license agreement for its proprietary CodeEvolver protein engineering platform technology with GlaxoSmithKline (GSK).
CDXS: 2.30 (-0.10), GSK: 45.66 (+0.04)
Codexis' (CDXS) CEO John Nicols on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:50PM CST
CDXS: 2.30 (-0.10)
Codexis misses by $0.06, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:09PM CST
CDXS: 2.30 (-0.10)
Codexis Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014
GlobeNewswire - Tue Nov 04, 3:03PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced financial results for the third quarter and nine months ended September 30, 2014.
CDXS: 2.30 (-0.10)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.88 (-0.05), ITRI: 40.92 (-0.72), AWAY: 30.97 (+0.17), OKE: 55.65 (-0.81), HR: 25.84 (+0.10), NYMT: 8.11 (-0.01), OCLR: 1.68 (+0.03), ENPH: 10.64 (+0.01), ADEP: 8.66 (-0.28), CBSO: 31.08 (+0.27), NSTG: 12.19 (+0.03), MITT: 19.03 (-0.15), CRTO: 38.20 (+0.92), FOXA: 34.99 (+0.35), OKS: 47.88 (-0.10), JMBA: 12.70 (-0.02), IVR: 16.26 (+0.04), CSU: 23.42 (+0.42), MYGN: 33.35 (+0.36), JIVE: 6.93 (+0.26), GAS: 51.65 (-0.47), COUP: 16.00 (-0.01), NRP: 12.58 (-0.25), MOSY: 1.79 (+0.12), COHR: 58.14 (-0.74), DOX: 47.58 (-0.12), CKEC: 28.48 (+0.08), OAS: 25.72 (-0.65), PAYC: 22.60 (+0.25), PCYC: 137.80 (+0.43), AXLL: 42.99 (-0.24), NP: 57.67 (-0.27), BIRT: 3.69 (-0.11), ATVI: 20.33 (-0.08), EXAM: 37.73 (+0.04), P: 18.45 (-0.34), JAZZ: 172.98 (-0.55), PBPB: 13.61 (-0.09), EXEL: 1.76 (-0.05), CERS: 4.42 (+0.23), DVN: 63.28 (-0.79), FEYE: 33.34 (+0.19), CHUY: 22.25 (-0.24), FRGI: 56.43 (-0.24), GHDX: 32.77 (-0.22), PACD: 6.69 (-0.18), BIO: 111.54 (-0.39), BIOL: 2.34 (-0.03), JKHY: 60.50 (-0.33), KAR: 33.74 (+0.09), CDXS: 2.30 (-0.10), MPO: 2.94 (-0.25), FANG: 64.76 (-0.05), CORT: 3.05 (-0.01), CALD: 15.63 (-0.01)
Codexis Appoints Pam P. Cheng, Merck Global Executive, to Board of Directors
GlobeNewswire - Mon Nov 03, 3:01PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Pam Cheng to its board of directors. Ms. Cheng is a 17-year veteran of Merck & Co. and is currently serving as President of MSD China, where she has direct responsibility for $1.3 billion in sales and approximately 4,000 employees, covering a wide functional scope which includes commercial, R&D, manufacturing and various business support organizations.
MRK: 59.54 (+0.23), CDXS: 2.30 (-0.10)
Industrial Enzymes: Carbohydrases, Proteases, Lipases & Others - 2014 Global Strategic Business Report
M2 - Wed Oct 29, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrwq4b/industrial) has announced the addition of the "Industrial Enzymes - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Industrial Enzymes in US$ Thousands by the following Product Segments: - Carbohydrases - Proteases - Lipases - Others The report also analyzes the following End-Use Segments: - Food & Beverage - Detergents & Other Cleaning Products - Textiles - Animal Feed - Ethanol Production - Others The report profiles 52 companies including many key and niche players such as: - AB Enzymes GmbH - Advanced Enzyme Technologies Ltd. - Amano Enzyme Inc. - Asahi Kasei Pharma Corporation - BASF SE - BioResource International, Inc. - Chr. Hansen A/S - Codexis, Inc. - DuPont Nutrition and Health - Direvo Biotech AG - Enzymatic Deinking Technologies LLC - Hayashibara Company - Novozymes A/S - Royal DSM Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competition 3. Market Trends, Issues And Drivers 4. Product Overview 5. Product Introductions/Innovations 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. The Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 52 (including Divisions/Subsidiaries - 60) - The United States (18) - Canada (1) - Japan (3) - Europe (29) - - France (7) - - Germany (7) - - The United Kingdom (2) - - Spain (1) - - Rest of Europe (12) - Asia-Pacific (Excluding Japan) (
- Latin America (1) For more information visit http://www.researchandmarkets.com/research/hrwq4b/industrial CDXS: 2.30 (-0.10)
Codexis reports November 4
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 7:39AM CDT
CDXS: 2.30 (-0.10)
Codexis to Report Third Quarter 2014 Financial Results on November 4
GlobeNewswire - Tue Oct 21, 7:11AM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will report third quarter financial results after the close of market on November 4, followed at 4:30 p.m. Eastern Time by a conference call and audio webcast at www.codexis.com.
CDXS: 2.30 (-0.10)
Market Maker Surveillance Report. AHPI, APT, LAKE, IBIO, CDXS, MPO, Losing Stocks With Lowest Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:11AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Allied Healthcare Products Inc (NASDAQ:AHPI), Alpha Pro Tech Ltd (NYSE:APT), Lakeland Industries Inc (NASDAQ:LAKE), Ibio Inc (NYSE:IBIO), Codexis Inc (NASDAQ:CDXS), Midstates Petroleum Company Inc (NYSE:MPO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
APT: 2.87 (-0.13), AHPI: 1.58 (-0.14), MPO: 2.94 (-0.25), CDXS: 2.30 (-0.10), IBIO: 1.08 (-0.03), LAKE: 11.39 (-0.85)
Codexis Appoints Biotechnology Industry Veteran, Kathleen Glaub, to Board of Directors
GlobeNewswire - Mon Sep 22, 7:07AM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Kathleen Sereda Glaub to its board of directors. Ms. Glaub's 30-year career in leadership positions with drug development and technology companies will bring strong company-building and business strategy experience to the Codexis board.
CDXS: 2.30 (-0.10)
Analyzing the Market for Cellulosic Ethanol - 2014
M2 - Wed Sep 17, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/38rww8/analyzing_the) has announced the addition of the "Analyzing the Market for Cellulosic Ethanol - 2014" report to their offering. This report is a complete handbook on this dynamic fuel source and its position in the global energy scenario. The report builds on the global energy industry and the consumption patterns which are fed by the traditional sources like Oil, Coal, Natural Gas, Nuclear Energy and Hydroelectricity. The report also presents a track on the global energy consumption patterns along with the resources being used for them. Taking into consideration the revenue cycles in the global energy markets, the report explains the revenue derived from these demand patterns from traditional sources as well as hydroelectric and wind energy. The report further also details each source individually. Taking a contrasting view point the report presents an in depth analysis of the global energy crisis and the growing recognition of unconventional energy sources for arresting this crisis. Key Topics Covered: A. Executive Summary B. Analyzing the Global Energy Industry C. Revenue Returns on Global Energy Markets D. Global Energy Demand & Supply Dynamics E. Looking at the Global Energy Crisis F. Emergence of Ethanol as an Energy Source G. Introduction to Cellulosic Ethanol H. Analyzing the Major Conversion Technologies: Producing Ethanol from Cellulosic Feedstocks I. Analyzing Ethanol Production from Different Feedstocks J. Analyzing the Utility of Ethanol in Transportation K. Commercializing Cellulosic Ethanol L. Factors Impact Growth of the Industry M. Challenges & Issues Facing the Industry N. Technological Patterns Prominent in the Industry O. Role of Industrial Biotechnology in the Development of Cellulosic Ethanol P. Production Patterns Q. Influence of Cellulosic Ethanol on the Farm Economy R. Ethanol Production and Use - Impact on the Economy S. Analyzing the Economics of Ethanol Production T. Analyzing the Regulatory Framework U. Government Incentives & Support Mechanisms V. Leading Industry Players - Abengoa Bioenergy Corporation - Archer Daniels Midland Co. - Aventine Renewable Energy Holdings - Cargill - Codexis, Inc - Dyadic International, Inc - Genencor International - Green Plains Renewable Energy. - Iogen Corporation - Lignol - Mascoma Corporation - NatureWorks, LLC - Novozymes - Pacific Ethanol, Inc. - Renova Energy (Wyoming Ethanol) - SunOpta - Tate & Lyle - The Andersons Inc. - U.S. BioEnergy Corporation - VeraSun Energy Corporation - Verenium - Xethanol BioFuels, LLC For more information visit http://www.researchandmarkets.com/research/38...lyzing_the
ADM: 50.81 (+0.10), GPRE: 33.01 (-0.60), CDXS: 2.30 (-0.10)
Global Synthetic Biology Market Forecasts and Opportunities, 2020
M2 - Tue Sep 02, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnnz65/global_synthetic) has announced the addition of the "Global Synthetic Biology Market (Products, Technologies, Applications and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. Global synthetic biology market was valued at $3.0 billion in 2013 and it is estimated to reach $38.7 billion by 2020, growing at a CAGR of 44.2% during the forecast period. Synthetic biology is a novel field that finds its origin at the intersection of biology and engineering. It involves designing and construction of biological systems or devices that can be applied in varied domains to get specified results. It's a multidisciplinary effort made by scientists to understand the functioning of biological organisms, cells & genes and implementation of artificial genetic processes to give specific characteristics to an organism. It can even be used to develop a completely new biological system. Assistance from government and private organizations, rising number of entities conducting research and declining cost of DNA sequencing and synthesizing are key driving factors of the market. Governments are providing funds to research organizations, assisting them to find novel applications of synthetic biology. Bio-safety & bio-security issues, ethical issues and regulations are key retraining factors of the market. The fact that synthetic biology can be misused has raised concerns all around the world. Further, there are possibilities of accidental release of pathogens or genetically modified organisms into free atmosphere. Report Scope Key Deliverables Market by Products - Enabling Products - DNA Synthesis - Oligonucleotide Synthesis - Enabled Products - Pharmaceuticals - Chemicals - Biofuels - Agriculture - Core Products - Synthetic DNA - Synthetic Genes - Synthetic Cells - XNA - Chassis Organisms Market by Technology - Enabling Technology - Genome Engineering - Microfluidics technologies - DNA synthesis & sequencing technologies - Bioinformatics technologies - Biological components and integrated systems technologies - Enabled Technology - Pathway engineering - Synthetic microbial consortia - Biofuels technologies Market by Application Research & Development - Chemicals - Agriculture - Pharmaceuticals & Diagnostics - Biofuels - Others (Environment, Biotechnology & Biomaterials, etc.) Companies Mentioned - Algenol Biofuels - BASF - BioAmber - BioSearch Technologies - Butamax Advanced Biofuels - Codexis Inc. - Dupont - GEN9 Inc. - Gensript Corporation - Origene Technologies - Synthetic Genomics For more information visit http://www.researchandmarkets.com/research/jn..._synthetic
CDXS: 2.30 (-0.10)
Codexis Reports Financial Results for the Second Quarter of 2014
GlobeNewswire - Wed Aug 06, 3:02PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced its financial results for the second quarter ended June 30, 2014.
CDXS: 2.30 (-0.10)
5 Stocks Ready for Breakouts
at The Street - Mon Aug 04, 9:14AM CDT
These stocks are within range of triggering breakout trades.
BLUE: 41.23 (+0.21), TSLA: 251.70 (+2.60), ZPIN: 15.02 (-0.98), OVTI: 26.62 (-0.38), CDXS: 2.30 (-0.10), ATRO: 50.88 (-0.80)
Codexis to Announce Second Quarter 2014 Financial Results on August 6, 2014
GlobeNewswire - Thu Jul 31, 3:43PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will host a live conference call and audio webcast on Wednesday, August 6, 2014 at 4:30 p.m. Eastern Time to discuss its second quarter 2014 financial results. The call and webcast will follow the release of second quarter financial results after market close. A recorded version of the call will be available approximately one hour after the call on the Investors section of the company's website, www.codexis.com, and will be archived for up to 30 days.
CDXS: 2.30 (-0.10)
Gordon Sangster to Join Codexis as Senior Vice President & Chief Financial Officer
GlobeNewswire - Mon Jul 28, 3:01PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that Gordon Sangster has agreed to join Codexis as Senior Vice President & Chief Financial Officer. Gordon, who will start on August 18, 2014, will manage all aspects of Codexis' financial and accounting functions and will report to John Nicols, President & Chief Executive Officer.
CDXS: 2.30 (-0.10)
Biotechnology Sector Trends Higher with Breakthrough Clinical Trials, Collaborations & License Agreements
PR Newswire - Wed Jul 16, 7:15AM CDT
Biotechnology Companies strive to improve cancer treatment and develop innovative therapies as biotech sector sees growth as well as registered success: GenSpera, Inc. (OTC: GNSZ), Codexis, Inc. (NASDAQ: CDXS), Eli Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Seattle Genetics (NASDAQ: SGEN).
JNJ: 109.07 (+0.32), SGEN: 36.89 (-0.91), PFE: 30.42 (unch), CDXS: 2.30 (-0.10), LLY: 67.68 (+0.28)
Why Codexis (CDXS) Stock Hit a One-Year High Today
at The Street - Tue Jul 15, 1:11PM CDT
Codexis (CDXS) soared to a 52-week high of $2.65 on Tuesday after the biocatalyst developer announced a technology licensing agreement with GlaxoSmithKline (GSK).
CDXS: 2.30 (-0.10)
Codexis licenses its protein engineering platform technology to GlaxoSmithKline
M2 - Tue Jul 15, 8:24AM CDT
Biocatalysts company Codexis (NasdaqGS:CDXS) disclosed on Monday the execution of a platform technology license agreement for its proprietary CodeEvolver protein engineering platform technology with GlaxoSmithKline (GSK).
CDXS: 2.30 (-0.10), GSK: 45.66 (+0.04)
